Sensitivity analysis of a reduced model of thrombosis under flow: Roles of Factor IX, Factor XI, and γ′-Fibrin

Jason Chen, Scott L. Diamond *
Department of Chemical and Biomolecular Engineering, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA, United States of America

* sld@seas.upenn.edu

Abstract

A highly reduced extrinsic pathway coagulation model (8 ODEs) under flow considered a thin 15-micron platelet layer where transport limitations were largely negligible (except for fibrinogen) and where cofactors (FVIIa, FV, FVIII) were not rate-limiting. By including thrombin feedback activation of FXI and the antithrombin-I activities of fibrin, the model accurately simulated measured fibrin formation and thrombin fluxes. Using this reduced model, we conducted 10,000 Monte Carlo (MC) simulations for ±50% variation of 5 plasma zymogens and 2 fibrin binding sites for thrombin. A sensitivity analysis of zymogen concentrations indicated that FIX activity most influenced thrombin generation, a result expected from hemophilia A and B. Averaging all MC simulations confirmed both the mean and standard deviation of measured fibrin generation on 1 tissue factor (TF) molecule per μm². Across all simulations, free thrombin in the layer ranged from 20 to 300 nM (mean: 50 nM). The top 2% of simulations that produced maximal fibrin were dominated by conditions with low antithrombin-I activity (decreased weak and strong sites) and high FIX concentration. In contrast, the bottom 2% of simulations that produced minimal fibrin were dominated by low FIX and FX. The percent reduction of fibrin by an ideal FXIa inhibitor (FXI = 0) ranged from 71% fibrin reduction in the top 2% of MC simulations to only 34% fibrin reduction in the bottom 2% of MC simulations. Thus, the antithrombotic potency of FXIa inhibitors may vary depending on normal ranges of zymogen concentrations. This reduced model allowed efficient multivariable sensitivity analysis.

Introduction

Blood clotting occurs under flow conditions in many circumstances of hemostasis or intravascular thrombosis. When tissue factor is exposed to the blood the coagulation cascade is triggered, resulting in the eventual generation of thrombin and the polymerization of fibrin. The molecular events of this protease cascade are well studied and computer simulations of isotropic coagulation (TF added to plasma) typically include 20 to 60 individual parameterized reactions [1–3]. The complexity is increased by the presence of flow, the participation of platelets...
in clot growth, and various strong couplings and feedbacks [4–6]. Detailed models of coagulation under flow often require 20 to 50 partial differential equations (PDEs) and about 100 parameters relating to initial concentrations and kinetic coefficients. Numerous reviews have discussed both continuum and particle-based numerical approaches [7]. The further goal of multiscale modeling seeks to deploy complex vascular flows with realistic models of platelet signaling and coagulation function [8–10], all of which is extremely demanding from a computation point of view. Reduced models offer advantages in bridging scales and in handling 3D coupled reaction-diffusion-convection problems.

For clotting isotropically in a tube or clotting under flow conditions, plasma zymogen variations can be studied by Monte Carlo simulation or with high throughput experiment to explore sensitivity to initial conditions [2]. Blood plasma contains zymogens whose concentrations vary in the healthy population [11]. These variations impact coagulation time as was seen in a sensitivity analysis that highlighted the most proximal FVIIa participating reactions [12]. Often, the time to generate thrombin is the key parameter used in sensitivity analysis [13]. For example, using a sensitivity analysis of a thin film compartment model of clotting under flow, Leiderman et al. identified an unexpected competitive reaction involving Factor V that influenced hemophilic severity [14]. However, these models often have reaction networks that do not include the dynamics of fibrin generation and the binding of thrombin to fibrin via a weak site and a strong site. Fibrin has ‘antithrombin-I activity’ which includes (i) thrombin exosite I binding to the low affinity (Kd~2.8 μM) site in the E Domain, (ii) thrombin exosite II binding the high affinity site (Kd~0.1 μM) in the D-domain of the alternative splice variant, γ’-fibrin (ogen), (iii) a potential bivalent interaction, and (iv) irreversible entrapment [15]. The γ’-fibrinogen splice variant represents about 6–8% of total γ’-chains, with γA/γ’ heterodimer representing 12–16% of total fibrinogen [16].

Typically, simulating reactions under flow requires PDE models, however the thin film approach can reduce the system to ordinary differential equations (ODEs) that include mass transfer coefficients [17] or accommodate transport limits with effectiveness factors (η = actual rate/ideal rate) [18]. In the present study, we explored the sensitivity of an extrinsic pathway model for a 15-micron film that was previously shown to simulate fibrin formation dynamics and thrombin generation dynamics.

**Methods**

The reduced model supported by experimental data to predict thrombosis under flow was described previously [18]. Briefly, the model simulates blood clotting under venous flow over collagen and TF (1 TF/μm²) with a 15-micron thick “core” region (δ = 15 μm, porosity ~0.5), features supported by direct imaging and experimental configuration. The effective volume for enzyme reaction and initial conditions are shown in S1 File. The blood was treated with high CTI (40 μg/mL) to inhibit FXIIa as discussed in [18,19] so the model does not include FXIIa. We have previously shown CTI at this concentration prevents the formation of F1.2 when whole blood is perfused through a device lacking collagen/TF. The model includes extrinsic tenase/FIXase activity, intrinsic tenase activity, prothrombinase activity, feedback activation of FXIa by thrombin, fibrin generation, and thrombin bindings to fibrin. The thin film assumption allowed the linearization of the Michaelis-Menton kinetics since zymogen concentrations are set constant to plasma levels. The reduced model (7 rates, 2 K_D values, and enzyme half-lives ~ 1 min) only required 3 adjustments from published values measured under static conditions to predict the elution rate of thrombin-antithrombin (TAT), fragment F1.2 with or without fibrin formation, and intrathrombus fibrin. For the clot effluent measurements of TAT where thrombin had time to be inhibited, 70% of the thrombin eluted from the clot was
considered complexed with antithrombin with the remaining 30% of eluted thrombin complexed with other inhibitors [19]. The schematic of the reduced model is shown in Fig 1A. The experimental data of fibrin dynamics and F1.2/ TAT flux with/without fibrin formation are shown in Fig 1B–1D. The simulation results compared to experimental data are shown in S1 File.

The initial concentration of 5 plasma zymogens (FXI, FIX, FX, FII, fibrinogen) and 2 fibrin binding sites (weak sites and $\gamma'$-sites) are obtained from literature value and shown in Table 1. The results for population-average initial concentrations on coagulation rates are shown in S1 File, including the dynamics of FIXa, FXa, FXIa, thrombin on different sites, Fibrin, and F1.2/ TAT flux. Sensitivity analysis evaluate the effect of each variable on model predictions. We followed a similar sensitivity analysis used by a recent study [20]. Although there are several ways for sampling [12], we varied the concentration of 7 variables (5 zymogens and 2 thrombin binding sites) $\pm$ 50% as described in [20]. First, we performed a local sensitivity test where the variables were changed one-at-a-time. For visualization, the change of the maximum concentration of each species over 800 sec, instead of whole dynamics, was shown with respect to a range of variant. We then performed 10,000 Monte Carlo simulations where all the variables were sample uniformly and independently between 50–150% from their baseline concentration.

https://doi.org/10.1371/journal.pone.0260366.g001
The dynamics of fibrin deposition (calibrated by D-dimer assay) in 8-channel devices has been used to evaluate coagulation in whole blood under flow [26–29]. Therefore, we marked the top and bottom 2% of the fibrin concentration and looked at the distribution of the 7 variables. To evaluate the potency of a perfect FXIa/FXI inhibitor, we can turn off the feedback pathway described in [18] by setting \( \alpha_6 \) and \( \alpha_7 \) (in Table 1, S1 File) to zero.

**Results**

**Local sensitivity analysis**

By thin film assumption, we were able to simplify the perfusion of CTI-treated (40 \( \mu \)g/mL, full FXIIa inhibition without effect on FXIa) whole blood clotting over collagen/tissue factor surface (250 \( \mu \)m, 1 TF/\( \mu \)m\(^2\)). Only 3 parameters were adjusted from literature to fit the measured TAT, F1.2 and fibrin generation data (± GPRP). The reactions and kinetic parameters used in the reduced model are shown in the Table 1. In Table 1, reactions 1, 2, and 3 displayed no transport limits (effectiveness factor = 1), while reactions 4, 5, and 6 were adjusted to fit the experimental data, consistent with the presence of transport limits (effectiveness factor < 1). Thus, only 3 parameters were adjusted from literature (\( \eta_4, \eta_5, \eta_6 < 1 \)) to fit the measured TAT, F1.2 and fibrin generation data (± GPRP), which could indicate the transport limits (especially for fibrinogen) or possible differences due to conditions on platelet membranes of whole blood experiments. With well mixed, substrate concentrations in the clot are set to be constant at plasma levels from literatures. The dynamics of the procoagulants, thrombin distribution, fibrin, flux of F1.2 and TAT predicted by the reduced model with the baseline of plasma protein levels and thrombin binding sites are shown in S1 File.

Importantly, the levels of plasma zymogens and fibrin binding sites for thrombin vary across a range in healthy individuals. Here, we analyze the sensitivity of the reduced model output of all species (FIXa, FXIa, FXa, thrombin on different sites, TAT/F1.2 flux and fibrin). We first used the method of changing a variant one-at-a-time to quantify the sensitivity of

| # | Reactions | Enzyme | \([S]_0\) | \(k_{cat} \text{ (s}^{-1}\)) | \(K_m \text{ (\mu M)}\) | \(A \text{ (s}^{-1}\)) | \(\eta\) | Ref |
|---|-----------|--------|---------|----------------|----------------|---------------|------|-----|
| 1 | FXa\(\rightarrow\)Xa | TF/VIIa | \(X_0 = 0.17 \text{ \mu M}\) | 1.15 | 0.24 | 0.46 | 1 | [21] |
| 2 | IX\(\rightarrow\)Ixa | TF/VIIa | \(IX_0 = 0.09 \text{ \mu M}\) | 1.8 | 0.42 | 0.32 | 1 | [2] |
| 3 | IX\(\rightarrow\)Xa | IXa/VIIa | \(X_0 = 0.17 \text{ \mu M}\) | 8.2 | 0.082 | 5.42 | 1 | [2] |
| 4 | II\(\rightarrow\)IIa | Xa/Va | \(II_0 = 1.4 \text{ \mu M}\) | 30 | 0.3 | 24.7 | 0.18 | [2,21,22] |
| 5 | II\(\rightarrow\)IIa | IIa | \(\alpha_{\text{fbg}} = 18 \text{ \mu M}\) | 80 | 6.5 | 5.88 | 0.05 | [2,21,23] |
| 6 | IXa\(\rightarrow\)Xla | Xa/p' | \(XI_0 = 31 \text{ nM}\) | 1.3\(\times10^{-4}\) | 0.05 | 4.98\(\times10^{-5}\) | 0.36 | [2] |
| 7 | IX\(\rightarrow\)IXa | Xa/p' | \(IX_0 = 0.09 \text{ \mu M}\) | 0.21 | 0.2 | 0.065 | 1 | [2,24] |

Simplified clotting reactions neglecting limits in activated cofactor generation, plasma zymogen concentrations, and kinetic parameters of coagulation where \(\eta\) is the effectiveness factor (actual rate with transport limits/theoretical maximum rate). For each reaction, \(\alpha = \frac{k_{cat}[S]}{K_m + [S]}\). Published kinetic parameters above were typically obtained with excess purified lipids containing phosphatidylycholine (PC) and phosphatidylserine (PS) as a laboratory mimic of the more biologically complex platelet membranes. Reversible binding of thrombin to the weak and strong site in fibrin was treated as kinetically-controlled, reversible adsorption. [18] (p’, activated platelet).

https://doi.org/10.1371/journal.pone.0260366.t001

The dynamics of fibrin deposition (calibrated by D-dimer assay) in 8-channel devices has been used to evaluate coagulation in whole blood under flow [26–29]. Therefore, we marked the top and bottom 2% of the fibrin concentration and looked at the distribution of the 7 variables. To evaluate the potency of a perfect FXIa/FXI inhibitor, we can turn off the feedback pathway described in [18] by setting \(\alpha_6\) and \(\alpha_7\) (in Table 1, S1 File) to zero.
each output, which was used by [20]. We changed a variant one-at-a-time at a range of 50% to 150% of normal with others fixed. The local sensitivity of thrombin concentration on different sites of fibrin are shown in Fig 2. The results suggest that FIX level is the most important factor for thrombin. When FIX level is increased 50% from the baseline, total thrombin and thrombin binding on to weak sites increase by 100% and 140%, and free thrombin and thrombin on $\gamma'$-sites increase by around 75% compared to baseline. Maximum thrombin concentration is less sensitive to the variation on both thrombin binding sites. A stronger effect was seen when the $\gamma'$-sites decreased by 50%, thrombin on weak sites and free thrombin increased by 80% and 40%. The variation leads to similar trend on procoagulant factors (FIXa, FXa, FXIa), and the results are shown on Fig 3. Variation in FXI has more effect on FXIa. Fibrin as the final product of the coagulation cascade did not change dramatically with the zymogen variations. The fibrin concentration stays within ±50% by varying each inputs. Lastly, there were similar effects on F1.2 and TAT flux (Fig 3E and 3F), but the effect on F1.2 was stronger.

Fig 2. Local sensitivity analysis of total thrombin, free, and bound thrombin in the clot. The change of intrathrombus thrombin concentration on different sites due to the variation of plasma protein levels or thrombin binding sites on fibrin. The levels were changed one-at-a-time.

https://doi.org/10.1371/journal.pone.0260366.g002
Fig 3. Local sensitivity analysis of procoagulants, fibrin, F1.2 flux, and TAT flux. The concentration change of FIXa (A), FXa (B), FXIa (C), fibrin (D), and flux of F1.2 (E) and TAT(F) due to the variation of plasma protein levels or thrombin binding sites on fibrin. The levels were changed one-at-a-time.

https://doi.org/10.1371/journal.pone.0260366.g003
Global sensitivity test

To further investigate how the MC sampling of parameters would impact the results of the reduced model, a global sensitivity analysis was performed. A total of 10,000 Monte Carlo simulations were conducted with 7 variables including the levels of 5 plasma protein and 2 thrombin binding sites. Each variable was sampled between 50 and 100% of their baseline uniformly and independently for every simulation. The resulting fibrin concentration for every simulation is shown in Fig 4A. The mean, standard deviation and range are shown in Fig 4B, and the fibrin concentration distribution at 780 sec are shown in Fig 4C. The mean and standard deviation of fibrin concentration are similar to the experimental results, shown in red in Fig 4A and 4B, where whole blood was perfused over collagen/TF surface followed by plasmin digestion and D-dimer ELISA [19]. The dynamic results and the distribution at 800 sec of thrombin and other species are shown in Fig 5 and S1 File. Normal range variation of 7 inputs leads to free thrombin ranging most from 20 to 300 nM. The simulation results of TAT and F1.2 Flux are shown in Fig 6, and they agree with experimental data (shown in red, [19]) of ELISA analysis of the effluent.

Conditioned inputs distribution

We performed 10,000 Monte Carlo simulations by varying 7 variables independently. We further focused on the model’s result on fibrin production and marked the top and bottom 2% of the final fibrin concentration shown in Fig 7A. The distribution of the plasma protein levels and thrombin binding sites of top and bottom 2% are shown in Fig 7B and 7C. By looking at the subset of top 2% of fibrin generated, the distribution of plasma FIX, FXI levels and gamma’-sites are narrower and skewed away from 100%. These suggest that the high levels of FIX and FXI and less γ’-sites are important and lead to more fibrin, which agreed with the local sensitivity analysis. For the subset of the bottom 2% of fibrin production conditions, low levels of FIX and FX led to less fibrin.

Feedback pathway has emerged as a novel target for antithrombotic pathways with potentially little effects on hemostasis [30] since Factor XI-deficient patients do not have severe hemophilia. Here we evaluated the effect of inhibiting FXIa by turning off the feedback pathway in our simulations. We first labeled the 2%, middle 50% and bottom 2% of the final fibrin concentration in the 10,000 simulations, and then set the FXIa = 0 to see the efficacy of the inhibitor. The results are shown in Fig 8. The top 2% of fibrin generators displayed a 71% fibrin reduction by an ideal FXIa inhibitor, whereas the middle 50% and bottom 2% of fibrin generators displayed 50% and 33% fibrin reduction by a perfect FXI inhibitor. Here we showed that the efficacy of feedback pathway inhibitor may vary within a normal range of zymogens.

Discussion

In this study, we used a reduced coagulation under flow model and performed a sensitivity analysis on the extrinsic pathway of coagulation. We first performed the local sensitivity analysis where each of 5 plasma zymogens and 2 fibrin binding sites for thrombin were varied individually ± 50% from their consensus values. This indicated that the level of FIX and γ’-binding sites are the most influential variables for most of the simulation ensembles. For the global sensitivity analysis, all 7 variables were changed simultaneously and independently from 50 to 150% of the consensus value. With 10,000 Monte Carlo simulations, we showed the distribution of each procoagulants in the model and found that the mean and standard deviation of fibrin generation and TAT and F1.2 flux met with the data measured from healthy donors [19,31]. We also showed that the FXIa inhibitor may
have different potency across normal ranged plasma protein and thrombin binding sites, and the top 2% of the final fibrin concentration has the stronger effect of 71% fibrin reduction.

Fig 4. Fibrin concentration of 10,000 simulations compared to experimental data of blood clotting over collagen/TF under venous flow rate. Fibrin concentration of 10,000 Monte Carlo simulations of 7 variables (A). The mean, standard deviation, range (B), and the distribution (C) of the simulations, with the experimental end-point estimation of fibrin concentration from the D-dimer ELISA (shown in red). The 7 variables of plasma protein levels and thrombin binding sites were generated uniformly and independently.

https://doi.org/10.1371/journal.pone.0260366.g004
Plasma levels vary among individuals in normal range [11]. Reviews has summarized situations where high levels of coagulation factor elevate thrombotic risk [32]. In a large population-based, case–control study studies, Leiden Thrombophilia Study, research showed that elevated FIX [33] and FXI [34] are related to higher risk for thrombosis. Models has been developed to study the sensitivity to initial clotting factor concentration, both under non-flow [12,35] and under flow [20]. With the reduced model, we highlighted the role of FXI and FIX as risk factors for thrombosis.

Thrombin binds to fibrin clot tightly and localizes on γ'-fibrin [19]. The bindings of thrombin in the clot not only minimize downstream coagulation, but also protects thrombin from antithrombin inhibition [25]. Studies suggested that the variant interacts with other plasma protein and influences on clot formation and strength [36,37]. Fibrinogen γ’ level varies in patients, changes during inflammation and associates with arterial and venous thrombosis clinically [38]. The association between γ'/total fibrinogen ratio and thrombosis remain unclear and somewhat controversial [39]. Some studies suggested that decrease ratio are associated with higher risk for thrombosis [40].

Fig 5. Total, free, and bound thrombin of 10,000 simulations of blood clotting over collagen/ TF under venous flow rate. The mean, standard deviation, range (A, C, E, G) and the distribution at 800 sec (B, D, F, H) of thrombin on different sites of 10000 MC simulation varying plasma protein levels and thrombin binding sites ± 50% uniformly and independently.

https://doi.org/10.1371/journal.pone.0260366.g005
model demonstrates that low level of γ'-fibrin is the dominant factor in top 2% fibrin generation and it increases thrombin flux and fibrin generation. These results confirm with the explanation that the antithrombin-I activity of fibrin affects coagulation and reduces thrombin and its further activation.

Interestingly, the model predicted a relatively weak sensitivity to fibrinogen levels. High fibrinogen levels are viewed in general as pro-thrombotic, however it is important to recognize that fibrinogen and the γ'-chain variant are acute response genes elevated during inflammation, which may be a complex co-factor for thrombotic risk. Interestingly, some studies have identified elevated fibrinogen as protective, perhaps due to its anti-thrombin-I activity. During the simulations of the model, a 50% reduction in fibrinogen concentration caused only < 10% reduction in fibrin formation, which was unexpected. However, in the multivariable context of the model of diverse initial condition sampling (Fig 7A), there are many situations where low fibrinogen (Z1 in Fig 7C) was occurring with the bottom 2% of simulations producing low fibrin.

Simulations give insights and help experimental design for further discovery in coagulations [41]. Recently, Link et al used the computationally driven approach to identify FV
Fig 7. Plasma protein levels and thrombin binding sites distribution of the subsets of top and bottom 2% of fibrin concentration of 10,000 simulations. Fibrin concentration of 10,000 Monte Carlo simulations of 7 variables varying uniformly and independently. Top 2% and bottom 2% are labeled (A). Plasma protein levels and thrombin binding sites distribution of top 2% (B) and bottom 2% of the simulations (C).

https://doi.org/10.1371/journal.pone.0260366.g007
as modifier for hemophilia, further confirm it with experiment, and propose a potential mechanism. Although there are limitations and our model only describes the thrombosis under venous flow over TF-surface, it emphasized crucial reactions which have been

![Graphs of fibrin concentration](https://doi.org/10.1371/journal.pone.0260366.g008)

**Fig 8.** The potency of the blockage of FXIa varies over the subsets of fibrin concentration. The effect of inhibition of FXIa on fibrin concentration of top 2% (A), middle 50% (B), and bottom 2% (C) of 10,000 simulations.
often overlooked. With emerging strategies targeting FXI [42], our results provide insights in variation in potency of the inhibitors within normal range of clotting factors. Despite of the simplicity, this reduced model may be useful for its coagulation phenotype and further implementation with multiscale modeling which includes platelet accumulation [4,8,10].

Supporting information

S1 File. Contains the supplement method and figures.

Author Contributions

Formal analysis: Jason Chen.

Funding acquisition: Scott L. Diamond.

Investigation: Jason Chen.

Methodology: Jason Chen.

Visualization: Jason Chen.

Writing – original draft: Jason Chen.

Writing – review & editing: Scott L. Diamond.

References

1. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002; 277: 18322–18333. https://doi.org/10.1074/jbc.M201173200 PMID: 11893748
2. Chatterjee MS, Denney WS, Jing H, Diamond SL. Systems biology of coagulation initiation: Kinetics of thrombin generation in resting and activated human blood. Beard DA, editor. PLoS Comput Biol. 2010; 6: e1000950. https://doi.org/10.1371/journal.pcbi.1000950 PMID: 20941387
3. Bungay SD, Gentry PA, Gentry RD, Bungay SD. A mathematical model of lipid-mediated thrombin generation. Math Med Biol. 2003. https://doi.org/10.1093/imammb/20.1.105 PMID: 12974500
4. Flamm MH, Colace TV, Chatterjee MS, Jing H, Zhou S, Jaeger D, et al. Multiscale prediction of patient-specific platelet function under flow. Blood. 2012; 120: 190–198. https://doi.org/10.1182/blood-2011-10-388140 PMID: 22517902
5. Leiderman K, Fogelson A. An overview of mathematical modeling of thrombus formation under flow. Thromb Res. 2014;133. https://doi.org/10.1016/j.thromres.2014.03.005 PMID: 24759131
6. Wu WT, Jamiołkowski MA, Wagner WR, Aubry N, Massoudi M, Antaki JF. Multi-Consituent Simulation of Thrombus Deposition. Sci Rep. 2017; 7: 1–16. https://doi.org/10.1038/s41598-016-0028-x PMID: 28127051
7. Brass LF, Diamond SL. Transport physics and bioreology in the setting of hemostasis and thrombosis. J Thromb Haemost. 2016; 14: 906–17. https://doi.org/10.1111/jth.13280 PMID: 26848552
8. Lu Y, Lee MY, Zhu S, Sinno T, Diamond SL. Multiscale simulation of thrombus growth and vessel occlusion triggered by collagen/tissue factor using a data-driven model of combinatorial platelet signalling. Math Med Biol. 2017; 34: 523–546. https://doi.org/10.1093/imammb/dqw015 PMID: 27672182
9. Tsiklidis E, Sims C, Sinno T, Diamond SL. Multiscale systems biology of trauma-induced coagulopathy. 2018; 1–10. https://doi.org/10.1002/wasbm.1418 PMID: 29485252
10. Xu Z, Chen N, Kamocka MM, Rosen ED, Alber M. A multiscale model of thrombus development. J R Soc Interface. 2008; 5: 705–722. https://doi.org/10.1098/rsif.2007.1202 PMID: 17925274
11. Danforth CM, Orteo T, Mann KG, Brummel-Ziedins KE, Everse SJ. The impact of uncertainty in a blood coagulation model. Math Med Biol. 2009; 26: 323–336. https://doi.org/10.1093/imammb/dtp011 PMID: 19451209
12. Danforth CM, Orteo T, Everse SJ, Mann KG, Brummel-Ziedins KE. Defining the Boundaries of Normal Thrombin Generation: Investigations into Hemostasis. PLoS One. 2012; 7: 30385. https://doi.org/10.1371/journal.pone.0030385 PMID: 22319567
13. Link KG, Stobb MT, Di Paola JA, Neeves KB, Fogelson AL, Sindi SS, et al. A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. 2018 [cited 27 Nov 2018]. https://doi.org/10.1371/journal.pone.0200917 PMID: 30048479

14. Link KG, Stobb MT, Sorrells MG, Bortot M, Ruegg K, Manco-Johnson MJ, et al. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A. J Thromb Haemost. 2020; 18: 306–317. https://doi.org/10.1111/jth.14653 PMID: 31562694

15. Kelley M, Leiderman K. A Mathematical Model of Bivalent Binding Suggests Physical Trapping of Thrombin within Fibrin Fibers. Biophys J. 2019; 117: 1442–1455. https://doi.org/10.1016/j.bpj.2019.09.003 PMID: 31586524

16. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma'). Proc Natl Acad Sci. 1980; 77: 5069–5073. https://doi.org/10.1073/pnas.77.9.5069 PMID: 6933547

17. Fogelson AL, Hussain YH, Leiderman K. Blood clot formation under flow: the importance of factor XI depends strongly on platelet count. Biophys J. 2012; 102: 10–18. https://doi.org/10.1016/j.bpj.2011.10.048 PMID: 2225793

18. Chen J, Diamond SL. Reduced model to predict thrombin and fibrin during thrombosis on collagen/tissue factor under venous flow: Roles of γ'-fibrin and factor Xla. PLoS Comput Biol. 2019; 15. https://doi.org/10.1371/journal.pcbi.1007266 PMID: 31381558

19. Zhu S, Chen J, Diamond SL. Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow. Arterioscler Thromb Vasc Biol. 2018; ATV-BAHA.118.310906. https://doi.org/10.1161/ATVBAHA.118.310906 PMID: 29724819

20. Link KG, Stobb MT, Di Paola J, Neeves KB, Fogelson AL, Sindi SS, et al. A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. 2018 [cited 14 Apr 2020]. https://doi.org/10.1371/journal.pone.0200917 PMID: 30048479

21. Leiderman K, Fogelson AL. Grow with the flow: A spatial-temporal model of platelet deposition and blood coagulation under flow. Math Med Biol. 2011; 28: 47–84. https://doi.org/10.1093/imammb/dqq005 PMID: 20439306

22. Nesheim ME, Tracy RP, Tracy PB, Boskovic DS, Mann KG. Mathematical Simulation of Prothrombinase. Methods Enzymol. 1992; 215: 316–328. https://doi.org/10.1016/0076-6879(92)15074-m PMID: 14353332

23. Higgins DL, Lewis SD, Shafer JA, Higgins DL, Lewis SD, Shaferg JA, et al. Steady State Kinetic Parameters for the Thrombin-catalysed Conversion of Human Fibrinogen to Fibrin. J Biol Chem. 1983; 258: 9276–9282. PMID: 6409903

24. Elizondo P, Fogelson AL. A Mathematical Model of Venous Thrombosis Initiation. Biophys J. 2016; 111: 2722–2734. https://doi.org/10.1016/j.bpj.2016.10.030 PMID: 28002748

25. Haynes LM, Orfeo T, Mann KG, Everse SJ, Brummel-Ziedins KE. Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates. Biophys J. 2017; 112: 1634–1644. https://doi.org/10.1016/j.bpj.2017.03.002 PMID: 28445754

26. Chen J, Verni CCCC, Jouppila A, Lassila R, Diamond SLSL. Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation. Thromb Res. 2018; 169: 143–151. https://doi.org/10.1016/j.thromres.2018.07.026 PMID: 30071479

27. Colace T V., Muthard RW, Diamond SL. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: Role of thrombin with and without fibrin. Arterioscler Thromb Vasc Biol. 2012; 32: 1466–1476. https://doi.org/10.1161/ATVBAHA.112.249789 PMID: 22516070

28. Zhu S, Diamond SL. Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay. Thromb Res. 2014; 134: 1335–1343. https://doi.org/10.1016/j.thromres.2014.09.030 PMID: 25308860

29. Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. Blood. 2015; 126: 1494–502. https://doi.org/10.1182/blood-2015-04-641472 PMID: 26136249

30. Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020; 135: 351–359. https://doi.org/10.1182/blood.2019000919 PMID: 31917385

31. Zhu S, Lu Y, Sinno T, Diamond SL. Dynamics of thrombin generation and flux from clots during whole human blood flow over collagen/tissue factor surfaces. J Biol Chem. 2016; 291: 23027–23035. https://doi.org/10.1074/jbc.M116.754671 PMID: 27605669

32. Nossent AY, Eikenboom JCJ, Bertina RM. Plasma Coagulation Factor Levels in Venous Thrombosis. Semin Hematol. 2007; 44: 77–84. https://doi.org/10.1053/j.seminhematol.2007.01.006 PMID: 17433899
33. Van Hylckama Vlieg A, Van Der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000; 95: 3678–3682. https://doi.org/10.1182/blood.v95.12.3678 PMID: 10845896

34. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. N Engl J Med. 2000. https://doi.org/10.1056/NEJM200003093421004 PMID: 10706899

35. Susree M, Anand M, Anand M, In AA. Importance of Initial Concentration of Factor VIII in a Mechanistic Model of In Vitro Coagulation. Acta Biotheor. 2018; 66: 201–212. https://doi.org/10.1007/s10441-018-9329-8 PMID: 29761301

36. Pieters M, Kotze RC, Jerling JC, Kruger A, Ariëns RAS. Evidence that fibrinogen γ regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. Blood. 2013; 121: 3254–3260. https://doi.org/10.1182/blood-2012-12-471482 PMID: 23422752

37. Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing chains. 2005. https://doi.org/10.1182/blood-2005-01-0240 PMID: 16002430

38. Rein-Smith CM, Anderson NW, Farrell DH. Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6. Thromb Res. 2013; 131: 89–93. https://doi.org/10.1016/j.thromres.2012.09.017 PMID: 23036532

39. Macrae FL, Domingues MM, Casini A, Ariëns RASS. The (Patho)physiology of Fibrinogen γ′. Semin Thromb Hemost. 2016; 42: 344–355. https://doi.org/10.1055/s-0036-1572353 PMID: 27071047

40. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood. 2005; 106: 4176–4183. https://doi.org/10.1182/blood-2005-05-2180 PMID: 16144795

41. Link KG, Stobb MT, Monroe DM, Fogelson AL, Neeves KB, Sindi SS, et al. Computationally Driven Discovery in Coagulation. Arterioscler Thromb Vasc Biol. 2020; 79–86. https://doi.org/10.1161/ATVBAHA.120.314648 PMID: 3315272

42. Gailani D, Gruber A. Factor XI as a Therapeutic Target. Arterioscler Thromb Vasc Biol. 2016; 36: 1316–1322. https://doi.org/10.1161/ATVBAHA.116.306925 PMID: 27174099